Exin Therapeutics

Executive Summary

Exin Therapeutics is a preclinical-stage biotechnology company developing novel therapies for neurodegenerative diseases, primarily Alzheimer's and Parkinson's. Founded in 2024 and based in San Diego, the company leverages deep insights into protein aggregation and neuronal dysfunction to design targeted treatments that address key unmet medical needs. Although still in early research phases, Exin's focus on fundamental disease mechanisms positions it to potentially differentiate from competitors. The company is actively advancing its lead candidates toward IND-enabling studies, with a lean team and strategic focus on core pathology. Given the high unmet need in neurodegeneration and Exin's innovative approach, the company represents a high-risk but potentially high-reward opportunity in the biotech landscape.

Upcoming Catalysts (preview)

• H2 2026Series A Financing60% success
• Q1 2027Lead Candidate Selection70% success
• Q3 2027Initiation of IND-Enabling Studies50% success